Table of Contents
<< Previous Issue | Dec 2020 (Vol: 2020, Issue: 12) | Next Issue >> |
- Section: Mergers & Acquisitions
-
Eli Lilly Continues Neuroscience Expansion with US$1.36 B Disarm Therapeutics Buy
-
Gilead Makes Virology Bet with MYR Buy
-
AstraZeneca Bolsters Immunology Footprint with US$39 B Alexion Buyout
-
Covis Group Acquires AMAG Pharmaceuticals for US$498 M
-
Bayer Highlights Cell and Gene Therapy Commitment with US$4 B Asklepios Buyout
- Section: Research & Development
-
Biogen Licenses Sage’s GABAA Modulators to Bolster CNS Pipeline
-
Merck KGaA Strengthens Synthetic Lethality Pipeline with US$6.9 B Artios Alliance